Piotr Swat / Shutterstock.com
Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, Kite Pharma, Juno Pharmaceuticals, Sloan Kettering, Yescarta, CAR-T, patent infringement, Federal Circuit
